{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:34:27Z","timestamp":1775277267560,"version":"3.50.1"},"reference-count":18,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Hemoglobin (Hb) Agrinio is a rare non-deletional a-globin mutation observed almost exclusively in Greek, Spanish or other Mediterranean families. The clinical manifestations of a carrier of a single Hb Agrinio mutation (single heterozygosity) depend on the concomitant presence or absence of other mutations or variants in the beta, alpha or other modifying genes. We present a Greek patient harboring a Hb Agrinio variant plus the - -Med alpha deletional allele, having an infrequent severe form of alpha thalassemia, in contrast to the typical alpha thalassemic patient and requiring regular red blood cell (RBC) transfusions and chelation treatment. We also provide a concise literature review regarding alpha thalassemic hemoglobin variants and their molecular and clinical combinations. A phase 2, double-blind, randomized, placebo-controlled, multicenter clinical trial to determine the efficacy and safety of luspatercept (BMS-986346\/ACE-536) for the treatment of anemia in adults with alpha thalassemia with the participation of our center is currently recruiting patients (NCT05664737).<\/jats:p>","DOI":"10.3390\/hematolrep15030050","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T12:45:53Z","timestamp":1691498753000},"page":"483-490","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concomitant Presence of Hb Agrinio and - -Med Deletion in a Greek Male Patient with Hemoglobinopathy H: More Severe Phenotype and Literature Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0041-5930","authenticated-orcid":false,"given":"Michael D.","family":"Diamantidis","sequence":"first","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6893-198X","authenticated-orcid":false,"given":"Stefania","family":"Pitsava","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Zayed","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Argyrakouli","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Karapiperis","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Chatzoulis","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Alexiou","sequence":"additional","affiliation":[{"name":"Radiology Department, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achilles","family":"Manafas","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Tsangalas","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Karakoussis","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, General Hospital of Larissa, 41221 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"ref_1","first-page":"83","article-title":"Gene test review. Alpha-thalassemia","volume":"13","author":"Galanello","year":"2011","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMra1404415","article-title":"The \u03b1-thalassemias","volume":"371","author":"Piel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.hoc.2017.11.006","article-title":"Clinical Classification, Screening and Diagnosis for Thalassemia","volume":"32","author":"Viprakasit","year":"2018","journal-title":"Hematol.\/Oncol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcmd.2017.09.004","article-title":"Molecular basis of \u03b1-thalassemia","volume":"70","author":"Farashi","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/03630269809113135","article-title":"An \u03b1-thalassemic hemoglobinopathy: Homozygosity for the HB Agrinio \u03b1 2-globin chain variant","volume":"22","author":"Kanavakis","year":"1998","journal-title":"Hemoglobin"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/03630269.2010.509224","article-title":"Variable and often severe phenotypic expression in patients with the \u03b1-thalassemic variant Hb Agrinio [\u03b129(B10)Leu\u2192Pro (\u03b12)]","volume":"34","author":"Douna","year":"2010","journal-title":"Hemoglobin"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/03630260802004103","article-title":"Hb Agrinio [\u03b129(B10)Le-->uPro (\u03b12)] in combination with --MED I. Results in a severe form of Hb H disease","volume":"32","author":"Felekis","year":"2008","journal-title":"Hemoglobin"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/03630260802173833","article-title":"Unstable and thalassemic \u03b1 chain hemoglobin variants: A cause of Hb H disease and thalassemia intermedia","volume":"32","author":"Wajcman","year":"2008","journal-title":"Hemoglobin"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"E393","DOI":"10.1002\/ajh.26687","article-title":"Homozygosity for the hyperunstable hemoglobin variant Hb Agrinio (HBA2:c.89T>C) leads to severe antenatal anemia: Eight new cases in three families","volume":"97","author":"Szepetowski","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1365-2141.2000.02448.x","article-title":"Phenotypic and molecular diversity of haemoglobin H disease: A Greek experience","volume":"111","author":"Kanavakis","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/03630260802507964","article-title":"Association of mild and severely unstable \u03b1 chain variants: The first observation of a compound heterozygote with Hb Setif [\u03b194(G1)Asp-->Tyr (\u03b12)] and Hb Agrinio [\u03b129(B10)Leu-->Pro (\u03b12)] in a Greek family","volume":"32","author":"Douna","year":"2008","journal-title":"Hemoglobin"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/03630269.2017.1397016","article-title":"First Cases of Hb Agrinio Described in Patients from the Republic of Macedonia","volume":"41","author":"Dimishkovska","year":"2017","journal-title":"Hemoglobin"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/03630269509005818","article-title":"Hb A2-Agrinio [\u03b443(CD2)Glu-->Gly(GAG-->GGG)]: A new \u03b4 chain variant detected in a Greek family","volume":"19","author":"Papadakis","year":"1995","journal-title":"Hemoglobin"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3109\/03630269.2012.733988","article-title":"Study of three families with Hb Agrinio [\u03b129(B10)Leu\u2192Pro, CTG>CCG (\u03b12)] in the Spanish population: Three homozygous cases","volume":"36","author":"Baiget","year":"2012","journal-title":"Hemoglobin"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1046\/j.1365-2141.1996.d01-1487.x","article-title":"The interaction of \u03b1 zero thalassaemia with Hb Icaria: Three unusual cases of haemoglobinopathy H","volume":"92","author":"Kanavakis","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_16","first-page":"43","article-title":"A case of late diagnosis of compound heterozygosity for Hb Adana (HBA2:c.179G>A) in trans to an \u03b1+- thalassemia deletion: Guilty or innocent","volume":"24","author":"Tampaki","year":"2020","journal-title":"Hippokratia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent \u03b2-Thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1016\/S2352-3026(22)00208-3","article-title":"Luspatercept for the treatment of anaemia in non-transfusion-dependent \u03b2-thalassaemia (BEYOND): A phase 2, randomised, double-blind, multicentre, placebo-controlled trial","volume":"9","author":"Taher","year":"2022","journal-title":"Lancet. Haematol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/3\/50\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:28:05Z","timestamp":1760128085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/3\/50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["hematolrep15030050"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep15030050","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}